

C-Path Welcomes Bayer Pharma as Newest Member of CPP



C-Path is excited to welcome Bayer Pharma as a the newest member of the organization's Critical Path for Parkinson's (CPP) Consortium. Bayer is a global leader in innovative drug development with over 140 years' experience delivering pharmaceuticals to patients in need. Bayer and its wholly owned subsidiary partner companies, BlueRock Therapeutics and Asklepios BioPharmaceutical, Inc. (AskBio), are envisioning a future where cell and gene therapies can revolutionize the way individuals with Parkinson's are treated. By exploring the potential of transformative cell and gene therapies, Bayer is committed to supporting the vision of CPP in advancing much needed drug development tools for Parkinson's clinical trials.

CPP is a global public-private partnership initiated in 2015 consisting of industry, multiple nonprofit organizations, academic partners, and advisors (FDA, EMA, NIH, and people living with Parkinson's), with the goal of accelerating the path to approval of therapies that improve the lives of people with Parkinson's.



The goal of the CPP Consortium is to broadly advance the drug development landscape for Parkinson's prevention and treatment by working collaboratively with the Parkinson's Disease global community to share data, knowledge, and resources towards the development and regulatory endorsement of novel drug development tools.

The consortium does this by prioritizing efforts focused on broadening populations for trial recruitment, collecting, understanding, and sharing real-world data, and by leveraging innovative technologies to capture what truly matters.

Learn more about CPP [here](#).